PhageNova Bio Overview
- Year Founded
-
2012
- Status
-
Private
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$10M
- Investors
-
3
PhageNova Bio General Information
Description
Operator of a gene-therapy-based biotechnology platform intended to use bacteriophages to treat cancer cells. The company's platform combines the targeting capability of bacteriophages and the sustained gene expression of adeno-associated viruses, enabling physicians to target specific cancer cells without harming healthy cells.
Contact Information
Website
www.phagenovabio.comCorporate Office
- Thomas O. Daniel Research Incubator and Collaboration Center
- 556 Morris Avenue, S7-F3
- Summit, NJ 07901
- United States
Corporate Office
- Thomas O. Daniel Research Incubator and Collaboration Center
- 556 Morris Avenue, S7-F3
- Summit, NJ 07901
- United States
PhageNova Bio Timeline
PhageNova Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Grant | 01-Jun-2022 | $10M | Completed | Clinical Trials - Phase 3 | ||
| 6. Secondary Transaction - Private | 01-Oct-2021 | Completed | Clinical Trials - Phase 3 | |||
| 5. Later Stage VC | 27-Mar-2020 | Completed | Clinical Trials - Phase 3 | |||
| 4. Early Stage VC (Series A) | 01-Jan-2016 | Completed | Clinical Trials - Phase 3 | |||
| 3. Equity Crowdfunding | Completed | Clinical Trials - Phase 3 | ||||
| 2. Early Stage VC | 05-Jun-2013 | $600K | Completed | Clinical Trials - Phase 3 | ||
| 1. Angel (individual) | $600K | $600K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
PhageNova Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PhageNova Bio Patents
PhageNova Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230241203-A1 | Enhancing immune responses through targeted antigen expression | Pending | 06-Jul-2020 | ||
| EP-4175674-A2 | Enhancing immune responses through targeted antigen expression | Pending | 06-Jul-2020 | ||
| EP-4175674-A4 | Enhancing immune responses through targeted antigen expression | Pending | 06-Jul-2020 | A61K39/215 |
PhageNova Bio Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| IBS Capital | Hedge Fund | Minority | ||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority |
PhageNova Bio FAQs
-
When was PhageNova Bio founded?
PhageNova Bio was founded in 2012.
-
Where is PhageNova Bio headquartered?
PhageNova Bio is headquartered in Summit, NJ.
-
What industry is PhageNova Bio in?
PhageNova Bio’s primary industry is Biotechnology.
-
Is PhageNova Bio a private or public company?
PhageNova Bio is a Private company.
-
What is PhageNova Bio’s current revenue?
The current revenue for PhageNova Bio is .
-
How much funding has PhageNova Bio raised over time?
PhageNova Bio has raised $8.6M.
-
Who are PhageNova Bio’s investors?
IBS Capital, , and have invested in PhageNova Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
